Case Reports| July 1999
Sildenafil Ameliorates Effects of Inhaled Nitric Oxide Withdrawal
Andrew M. Atz, MD;
Andrew M. Atz, MD
David L. Wessel, MD
(Atz) Assistant in Cardiology, Children's Hospital; Instructor in Pediatrics, Harvard Medical School.
(Wessel) Director, Cardiac Intensive Care Unit, Children's Hospital; Associate Professor of Pediatrics (Anaesthesia), Harvard Medical School.
From the Department of Cardiology, Children's Hospital, and the Departments of Pediatrics and Anaesthesia, Harvard Medical School, Boston, Massachusetts. Submitted for publication September 16, 1998. Accepted for publication February 18, 1999. Dr. Atz is supported by an award from the National Institutes of Child Health and Human Development (# P30HD27805) and a grant from the United States Food and Drug Administration. Dr. Wessel is supported by grants from the United States Food and Drug Administration (# FDR-001316–01) and the Research Endowment of Children's Hospital (# 89430–02).
Address reprint requests to Dr. Wessel: Cardiac ICU Office, Children's Hospital, 300 Longwood Avenue, Farley 653, Boston, Massachussetts 02115. Address electronic mail to:wessel@a1.tch.harvard.edu
Anesthesiology July 1999, Vol. 91, 307–310.
Andrew M. Atz, David L. Wessel; Sildenafil Ameliorates Effects of Inhaled Nitric Oxide Withdrawal . Anesthesiology 1999; 91:307–310 doi: https://doi.org/10.1097/00000542-199907000-00041
nitric oxide, sildenafil, cyclic gmp
INHALED nitric oxide (NO) is a selective pulmonary vasodilator with therapeutic importance in pulmonary hypertension and respiratory failure. NO increases intracellular cyclic guanosine monophosphate (cGMP), which stimulates smooth muscle relaxation. Phosphodiesterase type 5 (PDE5) is found in high concentrations in the lung and contributes substantially to cGMP degradation within vascular smooth muscle. [1] Abrupt discontinuation of NO may be complicated by life-threatening events, and phosphodiesterase activity may play a role in this phenomenon. [2] Sildenafil (Viagra; Pfizer Laboratories, New York, NY) is a potent and selective inhibitor of cGMP-specific PDE5, the predominant isoenzyme that hydrolyzes cGMP in the corpus cavernosum. [3] We hypothesized that sildenafil may potentiate pulmonary vasodilation with NO or ameliorate the deleterious effects of abrupt discontinuation of NO by increasing intracellular and circulating cGMP, preventing rapid depletion of cGMP when the gas is withdrawn.
A 6-week-old 3.1-kg female infant with complex bilateral pulmonary vein obstruction underwent surgical resection of an obstructive membrane within the left atrium. The postoperative period was complicated by suprasystemic levels of pulmonary hypertension with systemic hypotension. After obtaining informed written consent from the parents, a trial of inhaled NO was performed according to a protocol approved by the Food and Drug Administration and the Clinical Investigation Committee at Children's Hospital. Mean pulmonary artery pressure was selectively reduced from 57 mmHg to 33 mmHg during NO inhalation at 20 ppm. Radioimmunoassay measurements of cGMP (Amersham RPA 545; Amersham International Ltd., Buckinghamshire, United Kingdom) from a systemic artery increased from 12 pmol/ml at baseline to 28 pmol/ml with NO. Subsequent attempts to withdraw NO were associated with a rapid increase in pulmonary artery pressure, systemic hypotension, and oxygen desaturation. After the third unsuccessful attempt at withdrawal, NO was reinstituted, and a 1-mg dose of sildenafil was administered through a nasogastric tube. This dosage was approximately one half of the weight-adjusted dose for an adult (50 mg for a 70-kg man). Ninety minutes later NO again was withdrawn with minimal increase in pulmonary artery pressure, which remained stable over 30 min (Figure 1). cGMP nearly doubled after sildenafil administration (28 pmol/ml to 45 pmol/ml) and remained elevated after NO was withdrawn. NO was restarted to maximize clinically recovery, and the patient was later weaned without incident.
Figure 1. Continuous trace of systolic, mean, and diastolic systemic blood pressure (BP) and pulmonary artery blood pressure (PAP) recorded every minute. Withdrawal of NO initially (W1) rapidly produces pulmonary hypertension, systemic hypotension, and a 10% decrease in cyclic guanosine monophosphate (cGMP) after 2 min. A 1-mg dose of sildenafil causes mild additional pulmonary vasodilation and dramatically blunts the pulmonary hypertensive effect of NO withdrawal 90 min later (W2). cGMP levels nearly doubled from baseline and remained above baseline levels for 30 min after sildenafil.
A 3.5-kg newborn female infant with infradiaphragmatic total anomalous pulmonary venous connection that was obstructed underwent surgical connection on the day she was born. Systemic hypotension, low cardiac output, and pulmonary hypertension complicated the initial postoperative period. NO was administered via inhalation and immediately reduced mean pulmonary artery pressure from systemic to half-systemic levels; it was continued at 20 ppm. On the third postoperative day after failed withdrawal (mean pulmonary artery pressure increased to 40 mmHg within 3 min), NO was reinstituted, and 1 mg of sildenafil was administered via a nasogastric tube. NO was withdrawn 70 min later with only a mild (6 mmHg) increase in pulmonary artery pressure (peak mean, 28 mmHg). This pressure remained stable for 1 hr. cGMP levels were 19 pmol/ml on NO before withdrawal. One hour after NO reinstitution at 20 ppm and sildenafil administration, cGMP was 30 pmol/ml. cGMP remained greater than initial baseline levels at 15 (29 pmol/ml), 30 (24 pmol/ml) and 60 (23 pmol/ml) min after NO withdrawal.
A 4-month-old 4.1-kg male infant with severe bilateral pulmonary vein stenosis after neonatal repair of supracardiac total anomalous pulmonary venous connection underwent surgical revision. Postoperatively, the patient had moderately elevated mean pulmonary artery pressure decreased from 27 mmHg to 19 mmHg with NO at 80 ppm, whereas cGMP increased from 27 pmol/ml at baseline to 135 pmol/ml. Administration of NO was continued at 20 ppm. Three daily attempts to withdraw NO with the immediate appearance of suprasystemic pulmonary artery pressure resulted in failure. After the third failed attempt, a 1.1-mg dose of sildenafil was given via a nasogastric tube; NO was withdrawn 70 min later. Again, there was an immediate increase in pulmonary artery pressure with a time course and amplitude that was nearly identical to previous withdrawal attempts. However, cGMP levels showed that sildenafil administration caused only a slight increase in cGMP (from 19 to 22 pmol/ml). Presumably, because gastrointestinal absorption was a known problem in this patient, poor absorption hindered the effect of the drug, and placement of a jejunostomy tube for feeding was subsequently required. NO was again started, slowly weaned over the next week, and ultimately discontinued from 1 ppm after 16 days of therapy.
Rebound pulmonary hypertension caused by withdrawal of inhaled NO was markedly attenuated in two patients by increasing cGMP with sildenafil. In a third patient with poor gastrointestinal absorption, cGMP levels did not increase with sildenafil, and rebound pulmonary hypertension was not blunted. Rebound pulmonary hypertension is not unique to inhaled vasodilators, but its causes are unclear. Mechanisms underlying the adverse effects of NO withdrawal may involve reduced production of endogenous NO and reduced capacity to generate quickly cGMP when exogenous NO is discontinued. [4] Negative feedback inhibition by exogenous NO has been postulated to account for this observation [5] and has been demonstrated to exist for inducible [6] and endothelial [7] NO synthase in vitro. Decreased endogenous production of exhaled NO from smokers could also support a negative feedback theory. [8] PDE5 inhibition augments and prolongs responses to NO in animal models and increases the release of cGMP. [9] Dipyridamole, the only PDE5 inhibitor thus far described in humans, attenuated increases in pulmonary artery pressure after NO withdrawal following cardiac surgery. This may be related to inhibition of vascular smooth muscle cGMP degradation, although that was not confirmed with cGMP measurements. [2] However, dipyridamole has nonspecific effects and may also block adenosine reuptake in endothelial cells and erythrocytes. Dukarm et al. [10] showed that systemic hypotension is a limiting feature of dipyridamole when used in a lamb model of persistent pulmonary hypertension of the newborn.
In cases 1 and 2, we confirmed a near doubling of circulating cGMP using the newly available, more specific PDE5 inhibitor. In case 3, there was not a significant increase in cGMP after sildenafil administration. Because the latter child had generated a fourfold increase in cGMP from baseline when NO was initially begun, we were inclined to attribute the inability to attenuate the NO withdrawal response to poor drug absorption and failure to effect an increase in cGMP. Although cGMP is an intracellular second messenger, the precise source of plasma cGMP is unknown. However, our preliminary observation demonstrates an association between a successful increase in cGMP level and the blunting of the pulmonary hypertensive response to NO withdrawal. This study may support the important role of the phosphodiesterase system in the genesis and treatment of pulmonary hypertension.
We speculate that exogenous NO produces a negative feedback inhibition of NO synthase activity with a rapid reduction of pulmonary vascular smooth muscle cGMP when inhaled NO is abruptly withdrawn. Preliminary animal studies suggest that there is indeed a reduction in NO synthase enzyme activity but not gene expression, [11] consistent with the short duration of rebound pulmonary hypertension that we previously described in this population of patients with total anomalous pulmonary venous connection. [12] Alternative strategies aimed at increasing cGMP may facilitate withdrawal of NO. PDE5 inhibitors may be useful when NO is incompletely effective, when NO delivery must be interrupted for patient transport, or to assist in weaning from prolonged NO therapy. Sildenafil as an oral pulmonary vasodilator alone or in conjunction with NO merits further evaluation. Carefully designed studies of its possible therapeutic use and potential toxicity in the pediatric population may be warranted.
We do not advocate casual "off label" use of sildenafil as an oral pulmonary vasodilator, especially in children. Caution must be taken in patients who might have high circulating levels of cGMP, such as those with sepsis in whom small concentrations of a PDE5 inhibitor may precipitate significant hypotension. Sildenafil is contraindicated in patients receiving oral or intravenous nitrates, in whom refractory hypotension may ensue. Sildenafil is eliminated primarily by a hepatic route and is converted to an active metabolite. Both forms have terminal half-lives of approximately 4 hr in human adults. Patients with hepatic dysfunction and those taking drugs that interact with the cytochrome system may have reduced clearance of the sildenafil. Other limitations and unknown side effects must be carefully considered before using this drug.
Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD: Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 1998; 43:163-8
Ivy DD, Kinsella JP, Ziegler JW, Abman SH: Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998; 115:875-82
Boolell M, Gepi-Attee S, Gingell JC, Allen MJ: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78:257-61
Goldman AP, Haworth SG, Macrae DJ: Does inhaled nitric oxide suppress endogenous nitric oxide production? J Thorac Cardiovasc Surg 1996; 112:541-2
Buga GM, Griscavage JM, Rogers NE, Ignarro LJ: Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res 1993; 73:808-12
Assreuy J, Cunha FQ, Liew FY, Moncada S: Feedback inhibition of nitric oxide synthase activity by nitric oxide. Eur J Pharmacol 1993; 108:833-7
Ravichandran LV, Johns RA, Rengasamy A: Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol 1995; 268:H2216-23
Gerlach H, Rossaint R, Pappert D, Knorr M, Falke KJ: Autoinhalation of nitric oxide after endogenous synthesis in nasopharynx. Lancet 1994; 343:518-9
Ichinose F, Adrie C, Hurford W, Zapol W: Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J Appl Physiol 1995; 78:1288-95
Dukarm RC, Morin FC, Russell JA, Steinhorn RH: Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. Pediatr Res 1998; 44:831-7
Black SM, Heidersbach RS, McMullan DM, Fineman JR: Inhaled nitric oxide inhibits NOS activity in lambs: A potential mechanism for rebound pulmonary hypertension (abstract). Crit Care Med 1992; 27:A39
Atz AM, Adatia I, Wessel DL: Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996; 62:1759-64
Copyright 1999 by the American Society of Anesthesiologists.
Sildenafil Is a Pulmonary Vasodilator in Awake Lambs with Acute Pulmonary Hypertension
Anesthesiology (June 2000)
Sildenafil Prevents Cardiovascular Changes after Bone Marrow Fat Embolization in Sheep
Is Sildenafil Indicated in Treatment of Pulmonary Hypertension?
Treatment of Rebound Pulmonary Hypertension: Why Not Sildenafil?
Anesthesiology (December 2004)